Abstract
We analysed the outcome of 92 consecutive unrelated donor haematopoietic cell transplantations (UD-HCTs) performed in Spain to treat adult patients with CML in the first chronic phase (1CP). Patients' and donors' median age was 32 (15–49) and 36 (22–56) years, respectively. In all, 73 pairs (79%) matched for A, B±C and DRB1±DQB1 loci and 19 had ⩾1 mismatch. Their probability of survival and disease-free survival at 4 years were 50 and 46%, respectively. Pretransplant factors associated with a better survival were patient age <25 years (P=0.035), donor age ⩽36 years (P=0.012), use of cyclosporine since day –7 (P=0.001), and matching 8/8, 9/10 or 10/10 loci at allele level (P=0.003). In multivariate analysis only donor age (P=0.003; RR=3.1 (95% CI: 1.3–7.1)) and degree of HLA-matching (P=0.009; RR: 7.7 (95% CI: 1.8–33)) maintained their significance. The addition of these two variables to the EBMT prognostic score allowed an adequate risk assessment for patients receiving a UD-HCT during 1CP. Our analysis shows that in patients with a young and fully allele-matched donor, UD-HCT should be considered in the initial therapeutic algorithm due to its excellent outcome (92% survival at 2 years).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.
Radich JP, Olavarria E, Apperley JF . Allogeneic hematopoietic haematopoietic cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18: 685–702.
Appelbaum FR . Allogeneic transplantation for chronic myeloid leukemia. In: Blume KG, Forman SJ, Appelbaum F (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing: Maiden (MA), 2004, pp 1007–1017.
Anasetti C . Advances in unrelated donor hematopoietic cell transplantation. Haematologica 2003; 88: 246–249.
Bone Marrow Donor Wordwide webpage. http://www.bmdw.org.
REDMO webpage. https://www.fcarreras.org.
Tiercy JM, Bujan-Lose M, Chapuis B, Gratwohl A, Gmur J, Seger R et al. Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLAA/B/Cw/DRB1/B3/B5/DQB1 – matched donor? Bone Marrow Transplant 2000; 26: 437–441.
Carreras E, Tomas JF, Sanz G, Iriondo A, Boqué C, López J et al. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Espanol de Trasplante Hemopoyetico. Haematologica 2000; 85: 530–538.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL, McDOnald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathological study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Grey RJ . A case of K-sample test for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16: 1141–1154.
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187–220.
Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.
Lamparelli T, van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N et al. Bone marrow transplantation for chronic myeloid leukemia from unrelated and sibling donors: single center experience. Bone Marrow Transplant 1997; 20: 1057–1062.
Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood haematopoietic cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130–1135.
Tiercy JM, Passweg J, van Biezen A, Zander A, Kroger N, Gratwohl A et al. Chronic Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Isolated HLA-C mismatches in unrelated donor transplantation for CML. Bone Marrow Transplant 2004; 34: 249–255.
Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Viñas M, Filipovich A, Horowitz M et al. Impact of HLA-class I and class II high resolution matching on outcomes of unrelated donor BMT: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004; 104: 1923–1930.
Petersdorf EW, Anasetti C, Martin PJ, Gooley T, Radich J, Malkki M et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 2004; 104: 2976–2980.
Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043–2051.
Bowden RA, Sayers M, Flournoy N, Newton B, Benaji M, Thomas EFD et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006–1010.
Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C . Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255–4260.
Acknowledgements
The authors acknowledge the support received from Clara Pérez and Cristina Fusté, members of the REDMO. We thank Professor Ciril Rozman for his comments on the preparation of the manuscript.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Carreras, E., Jiménez, M., Gómez-García, V. et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 37, 33–40 (2006). https://doi.org/10.1038/sj.bmt.1705195
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705195
Keywords
This article is cited by
-
Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation
Bone Marrow Transplantation (2021)
-
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas
Bone Marrow Transplantation (2016)
-
Donor choice according to age for allo-SCT for AML in complete remission
Bone Marrow Transplantation (2013)
-
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings
Leukemia (2013)
-
The conundrum of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/*02:02 mismatches in unrelated hematopoietic SCT
Bone Marrow Transplantation (2011)